

Precipio Announces Q2-2026 Financial Results

Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position

NEW HAVEN, CT, UNITED STATES, August 17, 2026 /EINPresswire.com/ -- Specialty cancer diagnostics company [Precipio, Inc.](https://www.precipioinc.com) (NASDAQ: PRPO), announces financial results for the second quarter that ended June 30, 2026.

Precipio, Inc. is a [B2i Digital Featured Company](https://b2idigital.com/precipio-inc-1). See the company's in-depth profile at: <https://b2idigital.com/precipio-inc-1>

Below are some of the key financial performance metrics for the Company. For additional results please see the Company's Form 10-Q which was filed today.

Revenue – \$7.0M vs. \$6.7M in Q1-2026, and up 22% YoY from \$5.7M in Q2-2025. This comprised of \$6.1M in pathology revenue (up from \$6.0M in Q1) and \$0.9M in product revenue (up from \$0.66M in Q1).

Adjusted EBITDA – \$0.4M vs. \$(0.2)M in Q1-2026. The change was driven by increased revenues of \$0.3 million and a decrease in stock-based compensation expense of \$0.2M.

Cash flow – Cash Flow generated from operations was \$0.7M in Q2-2026; total increase in cash was \$0.5 million, resulting in an end of quarter cash balance exceeding \$3M, vs \$1.1M in Q2-



NASDAQ: PRPO

Precipio reported record quarterly revenue exceeding \$7 million, driven by continued customer growth, higher product sales, and positive operating cash flow.



NASDAQ: PRPO

Precipio delivered 22% year-over-year revenue growth in Q2 2026, ending the quarter with more than \$3 million in cash and positive Adjusted EBITDA.

2025.

“As anticipated, Q2 operating performance reflects a healthy recovery and continued momentum across the business, with customer growth generating quarterly revenue surpassing \$7M for the first time in Company history. Product revenues increased 21% from the previous high of \$750K in Q4-2025, and cash increased to over \$3M.” said Ilan Danieli, CEO of Precipio. “We’ve achieved this level of cash without a financing event, demonstrating the strength of our operations. We’re encouraged by the progress we’ve made and believe we are well positioned to continue building on this momentum.”

Additional information and a more in-depth discussion on the Company’s Q2-2026 performance will be provided in the shareholder call on August 17th, 2026, at 5 PM ET. The call will include remarks by management on the Company’s core business, followed by a moderated Q&A session.

EBITDA and Adjusted EBITDA Reconciliation and Explanation

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-GAAP financial measure that is widely used to evaluate operational performance and pre-tax profitability of emerging growth companies like ours. Management believes Adjusted EBITDA provides investors with a useful perspective on the Company’s financial health, particularly where non-cash amortization has an important impact on profitability.

Adjusted EBITDA as we define it modifies EBITDA by excluding the non-cash costs of employee stock options and unusual non-operating income and expense. Below is a reconciliation of Net Income, EBITDA and Adjusted EBITDA for the second quarter of 2026 and 2025:

EBITDA and Adjusted EBITDA Reconciliation (\$ in millions, unaudited)

Net income/(loss) (GAAP): \$(0.2) in Q2-2026 vs. \$0.1 in Q2-2025

Adjustments to net income/(loss):

Interest expense, net: \$0.0 vs. \$0.0

Income taxes: \$0.0 vs. \$0.0

Depreciation: \$0.0 vs. \$0.1

Amortization of intangibles: \$0.2 vs. \$0.2

EBITDA (non-GAAP): \$0.0 in Q2-2026 vs. \$0.4 in Q2-2025

Further adjustments to EBITDA:

Stock-based compensation expense: \$0.8 vs. \$0.4

Other significant (income) expenses: \$(0.4) vs. \$(0.9)

Adjusted EBITDA (non-GAAP): \$0.4 in Q2-2026 vs. \$(0.1) in Q2-2025

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio's reach to eradicate misdiagnosis.

Availability of Other Information About Precipio

For more information, please visit the Precipio website at <https://www.precipiodx.com/> or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (<https://www.precipiodx.com>), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing.

Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management's estimates, beliefs, assumptions and projections. Words such as "could," "may," "expects," "anticipates," "will," "targets," "goals," "projects," "intends," "plans," "believes," "seeks," "estimates," "predicts," and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based

on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management's estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Inquiries:

investors@precipiodx.com
+1-203-787-7888 Ext. 523

Media Contact:

David Shapiro
B2i Digital, Inc.
+1 212-579-4844
david@b2idigital.com

Visit us on social media:

[LinkedIn](#)
[Bluesky](#)
[Instagram](#)
[Facebook](#)
[YouTube](#)
[TikTok](#)
[X](#)
[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/934869602>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.